Loading...
Market
Story
Alumis Announces $316 Million IPO, Seeks $1 Billion Valuation
Jun 24, 2024, 02:50 PM
Alumis, an immunology biotech company, has announced its initial public offering (IPO) of 17.65 million shares priced between $16 and $18 per share. The company aims to raise $300 million through this IPO, which will support its TYK2 inhibitor through phase 3 psoriasis trials. Alumis is seeking a valuation of up to $1 billion in the US market. The proceeds from the planned IPO, tagged at $316 million, will also help fund a late-stage clinical trial for psoriasis.
View original story
Similar markets
Decrease by more than 20% • 25%
Change between -20% and +20% • 25%
Increase by 20% to 50% • 25%
Increase by more than 50% • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Above $300 million • 33%
Between $200 million and $300 million • 34%
Below $200 million • 33%
Outperforms S&P 500 • 25%
Underperforms S&P 500 • 25%
Outperforms Dow Jones • 25%
Underperforms Dow Jones • 25%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Decrease • 25%